The Queen Zone on MSN
New blood test could help spot aggressive prostate cancer earlier
For many men, a prostate cancer scare starts with one number. A PSA result comes back high, and ...
A pioneering blood test detected more than twice as many high-risk prostate cancer cases as current methods, paving the way for more effective screening. Research on more than 12,000 men aged 50 to 74 ...
More than three years after deciding to go test-optional permanently, Columbia University will again require applicants to submit standardized test scores, starting fall 2027. The university said in a ...
WASHINGTON (AP) — Younger students have regained ground academically after the pandemic's disruptions while older students' test scores continue to stagnate, according to the latest testing data ...
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. President Donald Trump has spoken up about achieving a “perfect” score ...
In a world of wild talk and fake news, help us stand up for the facts.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual ...
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the ...
The development cohort (DC) included men with PC (age ≥18 years) diagnosed in 2010-2014. Validation cohort 1 (V1) included men age 45 years and older within 1 year of PC diagnosis or near initiation ...
Ten common reasons your prostate test results might be falsely elevated Trump vs. Meloni 'popularity': What polls actually show as feud escalates Iran announces Strait of Hormuz closure after US ...
Trading with an implied upside of 60.5% and an RSI of 34.6, Tempus AI, Inc. (NASDAQ:TEM) has emerged as a notable oversold play in the AI sector. In a span of a week, Tempus AI, Inc. (NASDAQ:TEM) made ...
Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use Tempus AI, Inc., a leader in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results